STAA

STAAR SurgicalF

Nasdaq / Health Care Equipment & Services

At close

2026-07-22

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$33.00

+33.5% vs current

Most likely

Base case

45%

Probability

Target price

$23.00

-6.9% vs current

B-

Bear case

30%

Probability

Target price

$16.00

-35.2% vs current

AI sentiment snapshot

Latest data as of 2026-05-09

AI commentary

Primary-source tone improved after the April 8 preliminary sales release, and outside coverage pointed to a strong positive stock reaction around April 9, but this is not yet a true post-earnings setup because the company said on May 4 that the formal Q1 2026 release is scheduled for May 13, 2026, after market close [#IR-2026-05-04] [#8-K-2026-04-08]. That date mismatch lowers confidence in any T+3 read-through today. Delayed analyst target changes or estimate revisions were not available in the packet, so missing revision data should be treated as an evidence gap rather than positive confirmation. Overall tone is better than the prior negative baseline, but the memo remains monitoring-oriented because the strongest evidence is still preliminary rather than fully reported.

RankAlpha Sentiment Codex - 2026-05-09

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-13eventFirst-quarter 2026 results now scheduled for May 13, 2026High impact

The queue referenced a May 6, 2026 post-earnings follow-up, but STAAR said on May 4, 2026 that it will release first-quarter 2026 financial results and a shareholder letter after the market close on May 13, 2026. The key near-term test is whether reported revenue, adjusted EBITDA improvement, and market commentary validate the April preliminary sales update above $90 million and whether management provides clearer visibility on China and margins [#IR-2026-05-04] [#8-K-2026-04-08].

2026-11-13catalystChina inventory normalization and procedure recovery need to convert into durable reported growthHigh impact

STAAR said first-quarter preliminary growth was driven mainly by China, while March shareholder materials said China distributor inventory had normalized, demand stabilized, and 2026 should bring growth and improving profitability. If formal results and later quarters confirm that recovery without another inventory reset, the market can support a more durable rerating; if China demand or channel discipline slips again, the recovery case weakens [#8-K-2026-04-08] [#IR-2026-03-03] [#10-K-2026-03-03].

2026-12-31catalystCost discipline, Swiss manufacturing ramp, and EVO+ mix are the main margin follow-through leversHigh impact

Management's March shareholder letter framed 2026 around profit expansion, Swiss manufacturing scale-up for China supply, and early demand for EVO+ in China. If higher sales are matched by better yields, tariff mitigation, and mix, the company could move closer to sustainable profitability; if duplicative manufacturing costs or execution issues persist, operating leverage may lag the revenue recovery story [#IR-2026-03-03] [#10-K-2026-03-03].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-09 • Updated nightlySource: Internal modelMethodology